What CTMedic said. In addition if we ever trialed this in mild/moderate again with large population and exclusion of patients with no or very low symptoms we'd beat them in progression to severe/critical. But with everything else ongoing it's probably not worthwhile.

For longhaulers I've never ran across any other drug that has the properties to beat leronlimab.